DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
نویسندگان
چکیده
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. The mRNA expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments.
منابع مشابه
Why methylation is not a marker predictive of response to hypomethylating agents.
The azanucleotides azacitidine and decitabine have been shown to induce hematologic response and prolong survival in higher-risk myelodysplastic syndromes. They are inhibitors of DNA methyltransferase-1 and induce DNA-hypomethylation. Induction of apoptosis is also clinically relevant, in particular during the first treatment cycles, when cytopenia is a frequent side-effect. Since the hypomethy...
متن کاملGene Expression and Methylation Pattern in HRK Apoptotic Gene in Myelodysplastic Syndrome
Myelodysplastic syndromes (MDSs) are a clonal bone marrow (BM) disease characterized by ineffective hematopoiesis, dysplastic maturation and progression to acute myeloid leukemia (AML). Methylation silencing of HRK has been found in several human malignancies. In this study, we explored the association of HRK methylation status with its expression, clinical parameters and MDS subtypes in MDS pa...
متن کاملAzacitidine for the treatment of myelodysplastic syndromes (MDS).pub
Azacitidine is a pyrimidine nucleoside analogue with multiple mechanisms involved in its antineoplastic action. There is evidence that RNA metabolism is the primary target of this antimetabolite, although its inhibition of DNA methylation has been proposed as the main effect responsible for its clinical efficacy in myelodysplastic syndromes. In patients with myelodysplastic syndromes (MDS), aza...
متن کاملCharacterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Azanucleoside drugs such as 5-azacytidine (Vidaza) and 5-aza-2'-deoxycytidine (decitabine, Dacogen) function as DNA methyltransferase inhibitors in vitro and represent promising new drugs for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia. In this study, we aimed to determine the effect of decitabine on the genomic methylation level in MDS patients. Comparison of dif...
متن کاملMutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes
We evaluated the association of mutations in 34 candidate genes and response to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic mutations identified by next-generation sequencing. Most patients (93%) had ≥1 mutation (mean=2.6/patient). The overall response rate to azacitidine was 42%. No clinical characteristic was associated with response to azacitidine. Howeve...
متن کامل